Cargando…
Use of and Comorbidities Associated With Diagnostic Codes for COVID-19 in US Health Insurance Claims
This quality improvement study assesses the comorbidities associated with COVID-19 diagnostic codes in US health insurance claims.
Autores principales: | Yang, Kai-Cheng, Lee, Byungkyu, Ahn, Yong-Yeol, Perry, Brea L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8427377/ https://www.ncbi.nlm.nih.gov/pubmed/34495342 http://dx.doi.org/10.1001/jamanetworkopen.2021.24643 |
Ejemplares similares
-
Systematic Evaluation of State Policy Interventions Targeting the US Opioid Epidemic, 2007-2018
por: Lee, Byungkyu, et al.
Publicado: (2021) -
Diagnosis and management of hidradenitis suppurativa: Analysis of US insurance claims data
por: Xiong, Betty, et al.
Publicado: (2023) -
Validation of an administrative claims-based diagnostic code for pneumonia in a US-based commercially insured COPD population
por: Kern, David M, et al.
Publicado: (2015) -
Substitution of Nonpharmacologic Therapy With Opioid Prescribing for Pain During the COVID-19 Pandemic
por: Lee, Byungkyu, et al.
Publicado: (2021) -
Alopecia Areata Treatment Patterns, Healthcare Resource Utilization, and Comorbidities in the US Population Using Insurance Claims
por: Senna, Maryanne, et al.
Publicado: (2021)